Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function
Authors:
- Maciej J. Zamek-GliszczynskiMaciej J. Zamek-Gliszczynski
- J. Cory KalvassJKJ. Cory Kalvass
- Gary M. PollackGPGary M. Pollack
- Kim L. R. BrouwerKim L. R. Brouwer
- 1 February 2009
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (2) , 386-390
Abstract
The quantitative impact of excretory transport modulation on the systemic exposure to xenobiotics and derived metabolites is poorly understood. This article presents fundamental relationships between exposure and loss of a specific excretory process that contributes to overall clearance. The mathematical relationships presented herein were explored on the basis of hepatic excretory data for polar metabolites formed in the livers of various transporter-deficient rodents. Experimental data and theoretical relationships indicated that the fold change in exposure is governed by the relationship, 1/(1 – fe), where fe is the fraction excreted by a particular transport protein. Loss of function of a transport pathway associated with fe < 0.5 will have minor consequences ( 0.5. These mathematical relationships may be extended to other organs, such as the intestine and kidney, as well as to systemic drug exposure. Finally, the relationship between exposure and fe is not only applicable to complete loss of function of a transport pathway but also can be extended to partial inhibition scenarios by modifying the equation with the ratio of the inhibitor concentration and inhibition constant.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of the Role of Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 in Hepatic Basolateral Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Abcc3–– and Abcc4–– MiceThe Journal of Pharmacology and Experimental Therapeutics, 2006
- The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in MiceMolecular Pharmacology, 2006
- An integrated approach to model hepatic drug clearanceEuropean Journal of Pharmaceutical Sciences, 2006
- Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolitesEuropean Journal of Pharmaceutical Sciences, 2006
- ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2′,7′-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICEDrug Metabolism and Disposition, 2006
- DISPOSITION OF ORAL AND INTRAVENOUS PRAVASTATIN IN MRP2-DEFICIENT TR– RATSDrug Metabolism and Disposition, 2005
- Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in HumansThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)Journal of Biological Chemistry, 2002
- Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradientJournal of Gastroenterology and Hepatology, 1996
- Kinetics of drug-drug interactionsJournal of Pharmacokinetics and Biopharmaceutics, 1973